The speaker is bullish, noting the stock 'rally's like crazy' and that they still own shares, suggesting a belief it may continue to perform well.

A new long position based on a high-risk, high-reward thesis. The speaker believes if the company's drug works, the stock could see a 20x-30x return, arbitraging the valuation gap with comparable companies.